Sugapriya Dhanasekaran | Cancer Science | Best Academic Researcher Award

Published on by Oncology

Best Academic Researcher Award

Sugapriya Dhanasekaran
Manipal University College Malaysia

Sugapriya Dhanasekaran is an academic researcher affiliated with Manipal University College Malaysia, Malaysia. Her research profile is associated with the subject area of Cancer Science. This academic recognition article presents her institutional affiliation, bibliometric information, research-related publications supplied for the profile, and suitability for consideration for the Best Academic Researcher Award at the International Research Awards on Oncology and Cancer Research.

Sugapriya Dhanasekaran
Affiliation Manipal University College Malaysia
Country Malaysia
Scopus ID 55536226300
Documents 53
Citations 920
h-index 18
Subject Area Cancer Science
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-0905-7906

Abstract

Sugapriya Dhanasekaran is affiliated with Manipal University College Malaysia and is associated with the academic subject area of Cancer Science. Her supplied bibliometric profile reports 53 documents, 920 citations, and an h-index of 18. These indicators provide quantitative information about research productivity and citation activity. The publication records supplied alongside the profile include studies involving biomaterials, hydrogel polymers, clinical treatment procedures, laser applications, and nanocrystalline materials. However, the supplied publication records contain contributor names that do not identify Sugapriya Dhanasekaran as an author.[1]

Keywords

  • Sugapriya Dhanasekaran
  • Cancer Science
  • Academic Research
  • Research Publications
  • Bibliometric Indicators

Introduction

Academic research contributes to the advancement of scientific knowledge through systematic investigation, publication, collaboration, and dissemination of findings. In biomedical and cancer-related disciplines, research activities can support the understanding of disease mechanisms, therapeutic approaches, clinical procedures, and emerging scientific applications.

Research Profile

The available profile information identifies Sugapriya Dhanasekaran as affiliated with Manipal University College Malaysia. The academic subject area provided for this recognition profile is Cancer Science. Her reported Scopus author identifier is 55536226300, which can be used to locate and verify the associated bibliographic record through Elsevier’s Scopus platform.[1]

Research Contributions

The publication information provided for this article covers several scientific and biomedical topics, including hydrogel-based polymers, clinical treatment procedures, laser-assisted therapeutic applications, and nanocrystalline materials. These topics illustrate the multidisciplinary nature of biomedical research, where materials science, clinical medicine, and technological development can intersect.

Publications

The following bibliographic records were included in the supplied material. They are presented for reference and bibliographic transparency. The contributor information does not establish that Sugapriya Dhanasekaran authored these publications. The records should be cross-checked against the researcher’s Scopus profile before being included in an attributed publication list.

  1. Hydrogel tissue expanders for stomatology. Part I. Methacrylate-based polymers.
  2. Infantile hemangiomas. Current treatment procedures | Infantilní hemangiomas. Současné tělečné protředky.
  3. Direct and indirect treatment of pain with lasers – Update 2016.

Research Impact

Research impact can be assessed through multiple dimensions, including scholarly publications, citations, research collaboration, methodological contributions, and the relevance of findings to scientific or clinical practice. The supplied profile reports 53 documents, 920 citations, and an h-index of 18 for Sugapriya Dhanasekaran. These indicators suggest a measurable scholarly publication and citation record, subject to confirmation against the current indexed author profile.

Award Suitability

The Best Academic Researcher Award recognizes researchers who demonstrate sustained academic engagement, scholarly productivity, and contributions to their respective research disciplines. The International Research Awards on Oncology and Cancer Research provides a platform for recognizing research activities and academic achievements associated with oncology and related scientific fields.Based on the supplied profile, Sugapriya Dhanasekaran has several bibliometric indicators that may be considered during an academic recognition assessment:

Conclusion

Sugapriya Dhanasekaran is presented in this academic recognition profile as a researcher affiliated with Manipal University College Malaysia, Malaysia, with Cancer Science identified as the relevant subject area. The supplied bibliometric information reports 53 documents, 920 citations, and an h-index of 18. These indicators offer a quantitative perspective on the research profile and provide information relevant to academic recognition.

References

  1. Elsevier. (n.d.). Scopus author details: Sugapriya Dhanasekaran, Author ID 55536226300. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=55536226300
  2. Hrib, J., Sirc, J., Lesny, P., Hobzova, R., Duskova-Smrckova, M., Michalek, J., & Smucler, R. (2017). Hydrogel tissue expanders for stomatology. Part I. Methacrylate-based polymers. Journal of Materials Science: Materials in Medicine. DOI: 10.1007/s10856-016-5818-y.
    https://www.researchgate.net/profile/Sugapriya-Dhanasekaran-3
  3. Large scale preparation of up-converting YF₃:YbEr nanocrystals with various sizes by solvothermal syntheses using ionic liquid bmimCl. Journal of Fluorine Chemistry. DOI: 10.1016/j.jfluchem.2016.05.015.
    https://doi.org/10.1016/j.jfluchem.2016.05.015
  4. Lippert, J., Šmucler, R., & Vlk, M. (2013). Fractional carbon dioxide laser improves nodular basal cell carcinoma treatment with photodynamic therapy with methyl 5-aminolevulinate. Dermatologic Surgery. DOI: 10.1111/dsu.12242.
    https://doi.org/10.1111/dsu.12242
  5. ORCID. (n.d.). Sugapriya Dhanasekaran researcher identifier.
    https://orcid.org/0000-0002-0905-7906

Farshad Banouei | Oncology Case Reports | Excellence in Innovation

Published on by Oncology

Excellence in Innovation

Farshad Banouei
Hasheminjad Kidney Center, School of Medicine, Iran

Farshad Banouei
Affiliation Hasheminjad Kidney Center, School of Medicine, Iran University of Medical Sciences
Country Iran
Scopus ID 58574525400
Documents 5
Citation 2
h-index 1
Subject Area Oncology Case Reports
Event International Research Awards on Oncology and Cancer Research

Farshad Banouei is a researcher affiliated with Hasheminjad Kidney Center, School of Medicine, Iran University of Medical Sciences, Iran. The research recognition profile titled Excellence in Innovation highlights the importance of scientific contributions, interdisciplinary research, and innovation in advancing medical knowledge. The supplied publication records cover subjects including biomaterials, laser-based treatment approaches, dermatological interventions, nanomaterials, and clinical treatment research.

Abstract

Scientific innovation in medicine involves the development and evaluation of new materials, therapeutic techniques, diagnostic approaches, and clinical interventions. The supplied publication records associated with this research profile represent several areas of biomedical investigation, including hydrogel-based tissue expansion, laser-assisted treatment, photodynamic therapy, nanocrystal synthesis, and clinical management of medical conditions. These subjects demonstrate the interdisciplinary nature of contemporary biomedical research and the importance of collaboration across clinical medicine, materials science, and healthcare technology.

Keywords

Oncology Case Reports, Biomedical Research, Medical Innovation, Clinical Research, Laser Therapy, Photodynamic Therapy, Biomaterials, Hydrogel Polymers, Nanocrystals, Tissue Engineering, Cancer Research, Dermatological Treatment, Medical Materials Science, Therapeutic Development, Translational Medicine.

Introduction

Medical research continues to evolve through the integration of clinical knowledge, advanced materials, and innovative therapeutic technologies. Developments in biomaterials and tissue engineering contribute to the investigation of materials suitable for medical applications, while laser-based treatment methods provide additional approaches for managing selected clinical conditions. Similarly, nanomaterial research expands opportunities for investigating materials with specialized physical and chemical properties.

Research Profile

Farshad Banouei is presented in this recognition profile with an institutional affiliation at Hasheminjad Kidney Center, School of Medicine, Iran University of Medical Sciences, Iran. The research subject area identified for the profile is Oncology Case Reports. The supplied publication information provides a broader multidisciplinary scientific context, including biomaterials, clinical treatment procedures, laser applications, and nanomaterial synthesis.

Research Contributions

  • Biomaterials and tissue engineering: Research on methacrylate-based hydrogel polymers examines materials developed for tissue expansion applications in stomatology, contributing to the broader investigation of polymer-based medical materials.[1]
  • Clinical treatment research: Publications addressing infantile hemangiomas describe treatment procedures and clinical management considerations for a vascular condition encountered in pediatric medicine.[2]

Publications

The following selected bibliographic records were supplied for this academic profile. They are presented with their available journal, year, DOI, and contributor information. The records should not be interpreted as independently verified publications authored by Farshad Banouei, since the supplied contributor lists do not include that name.

  1. Hydrogel tissue expanders for stomatology. Part I. Methacrylate-based polymers.
  2. Infantile hemangiomas. Current treatment procedures | Infantilní hemangiomas. Současné tělečné protředky.
  3. Direct and indirect treatment of pain with lasers – Update 2016.

Research Impact

The supplied publications address research questions across several areas of biomedical science. Work on hydrogel polymers contributes to the scientific literature on biomaterials and their potential applications in tissue-related procedures. Investigations into laser-assisted treatment and photodynamic therapy provide clinical perspectives on therapeutic techniques, including approaches studied in dermatology and pain management. Nanocrystal synthesis research contributes to materials chemistry and the development of specialized nanoscale materials.

Award Suitability

The Excellence in Innovation recognition theme under the International Research Awards on Oncology and Cancer Research highlights scientific originality, research development, and contributions that may support progress in medical and biomedical disciplines.The multidisciplinary subjects represented in the supplied publication records offer potential areas for evaluating innovation in clinical treatment, biomedical materials, and therapeutic research. Relevant evaluation considerations may include:.

Conclusion

Excellence in medical innovation depends on sustained scientific investigation, interdisciplinary collaboration, and the translation of research findings into meaningful biomedical applications. The supplied publication records demonstrate the breadth of topics represented in contemporary biomedical and clinical literature, ranging from hydrogel-based materials and nanocrystal synthesis to laser-assisted therapies and photodynamic treatment.

References

  1. Google scholar profile. Hydrogel tissue expanders for stomatology. Part I. Methacrylate-based polymers. Journal of Materials Science: Materials in Medicine.
    https://scholar.google.com/citations?user=topjvN4AAAAJ&hl=en
  2. Šmucler, R., & Jenčová, J. (2016). Direct and indirect treatment of pain with lasers – Update 2016. Disease.
    Scopus
    https://www.scopus.com/authid/detail.uri?authorId=58574525400
  3. Bartůněk, V., Rak, J., Pelánková, B., Junková, J., Mezlíková, M., Král, V., Kuchař, M., Engstová, H., Ježek, P., & Šmucler, R. (2016). Large scale preparation of up-converting YF3:YbEr nanocrystals with various sizes by solvothermal syntheses using ionic liquid bmimCl. Journal of Fluorine Chemistry.
    https://doi.org/10.1016/j.jfluchem.2016.05.015
  4. Lippert, J., Šmucler, R., & Vlk, M. (2013). Fractional carbon dioxide laser improves nodular basal cell carcinoma treatment with photodynamic therapy with methyl 5-aminolevulinate. Dermatologic Surgery.
    https://doi.org/10.1111/dsu.12242

Tamara Voninski | chemotherapy | Best Research Article Award

Published on by Oncology

Best Research Article Award

Tamara Voninski
University of Sydney, Australia

Tamara Voninski
Affiliation University of Sydney
Country Australia
Subject area Chemotherapy
Award category Best Research Article Award
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-8556-0466

The Best Research Article Award is a recognition category associated with the International Research Awards on Oncology and Cancer Research. This article presents a structured academic profile for Tamara Voninski, listed with the University of Sydney in Australia, and identifies chemotherapy as the supplied subject area. The available publication records accompanying the request contain studies on biomaterials, clinical treatment, laser-based interventions and photodynamic therapy.

Abstract

This article outlines an academic recognition profile for Tamara Voninski in the context of the Best Research Article Award presented under the International Research Awards on Oncology and Cancer Research. The supplied information identifies the University of Sydney, Australia, as the researcher’s affiliation and chemotherapy as the relevant subject area. The accompanying bibliographic material describes five publications covering polymer-based hydrogel tissue expanders, infantile hemangioma treatment, laser-based pain management, up-converting nanocrystals and laser-assisted photodynamic therapy for nodular basal cell carcinoma. [1] [2]

Keywords

Best Research Article Award; oncology; cancer research; chemotherapy; biomedical research; clinical therapeutics; photodynamic therapy; laser medicine; biomaterials; academic recognition; research evaluation; scientific publications.

Introduction

Research article recognition can highlight the contribution of peer-reviewed scholarship to scientific knowledge, clinical practice and the development of new approaches to health care. In oncology, research spans cancer biology, chemotherapy, treatment response, supportive care, drug delivery and multidisciplinary clinical interventions. Evaluating a candidate for an article-based award requires reliable evidence of authorship, the quality and relevance of the nominated article, and its contribution to the selected field.

Research Profile

The supplied profile information identifies Tamara Voninski as affiliated with the University of Sydney in Australia. Chemotherapy is the specified subject area for this recognition profile. The information provided does not include a verified Scopus author identifier, a complete author bibliography, publication totals, citation counts or an h-index. These indicators are therefore marked as unverified rather than estimated.

Research Contributions

The supplied bibliography illustrates several research themes that may be relevant to biomedical and clinical science. These themes are described here as characteristics of the supplied literature, not as confirmed contributions by Tamara Voninski. Establishing individual contribution requires checking the author list of each publication against a verified researcher profile.

Publications

The following bibliographic records were included in the source material. They are presented for reference and research-context purposes only. The supplied contributor information does not establish that these publications belong to Tamara Voninski. Publication details and DOI metadata should be checked against the publisher’s record before being used in a formal award nomination.

  1. Hydrogel tissue expanders for stomatology. Part I. Methacrylate-based polymers.
    Journal of Materials Science: Materials in Medicine, 2017. Journal article.
  2. Infantile hemangiomas. Current treatment procedures.
    Supplied alternate title: “Infantilní hemangiomas. Současné tělečné protředky.”
    Czech-Slovak Pediatrics, 2017. Journal article.
  3. Direct and indirect treatment of pain with lasers — Update 2016.
    Disease, 2016. Journal article, as identified in the supplied record.
    Scopus EID: 2-s2.0-84992323214.

Research Impact

Research impact may be assessed through the originality of a study, the rigor of its methods, its contribution to existing knowledge, its relevance to clinical or scientific problems and the extent to which its findings are used by subsequent research. Citation indicators can supplement this assessment, but they do not independently establish methodological quality, clinical benefit or an individual’s contribution to a collaborative publication.

Award Suitability

The Best Research Article Award category is presented here in the context of the International Research Awards on Oncology and Cancer Research. A substantive suitability assessment requires the specific article nominated by the researcher, a verified author list and evidence demonstrating the article’s contribution to oncology or cancer research. The supplied information does not identify a nominated article authored by Tamara Voninski or establish an award decision.

Conclusion

This article documents the supplied academic recognition information for Tamara Voninski, identified with the University of Sydney in Australia, in the context of the Best Research Article Award. Chemotherapy is the stated subject area, while the accompanying bibliographic records describe research across several biomedical disciplines. Because the listed contributors do not establish a connection to the named researcher, these papers cannot be treated as evidence of her publication record without further verification.

References

  1. ORCID. (n.d.). ORCID: Connecting research and researchers. ORCID.
    https://orcid.org/0000-0002-8556-0466
  2. University of Sydney. (n.d.). Official university website.
    https://www.sydney.edu.au/
  3. Pencis. (n.d.). International Research Awards on Oncology and Cancer Research. Official event website.
    https://oncology.pencis.com/

Stavros derdas | Best Review Article Award | Cancer Biomarker

Published on by Oncology

Best Review Article Award

Stavros derdas
Aegean College

Stavros derdas
Affiliation Aegean College
Country Greece
Scopus ID 6505579887
Documents 17
Citations 487
h-index 9
Subject Area Cancer Biomarker
Event International Research Awards on Oncology and Cancer Research

Stavros derdas is a researcher affiliated with  research activity in the area of cancer biomarkers. The supplied bibliometric record identifies 17 documents, 487 citations, and an h-index of 9 under Scopus Author ID 6505579887. These indicators provide a bibliometric description of the research record and should be interpreted in the context of publication field, document type, citation practices, and database coverage. [1]

Abstract

This academic recognition profile presents STAVROS DERDAS in connection with the Best Review Article Award and the subject area of Cancer Biomarker. The profile is based on the supplied institutional and bibliometric information, including affiliation with AEGEAN COLLEGE, Greece, Scopus Author ID 6505579887, 17 documents, 487 citations, and an h-index of 9. Cancer biomarkers constitute an important research domain within contemporary oncology because biomarkers may support risk assessment, screening, diagnosis, prognosis, treatment-response prediction, and disease monitoring. Their translation into clinical practice requires analytical validation, clinical validation, and assessment of clinical utility. [2] Contemporary research additionally encompasses genomic, transcriptomic, proteomic, circulating, and liquid-biopsy approaches, with continuing emphasis on reproducibility and clinical validation. [3]

Keywords

STAVROS DERDAS; Cancer Biomarker; Cancer Research; Oncology; Biomarker Discovery; Biomarker Validation; Precision Oncology; Diagnostic Biomarkers; Prognostic Biomarkers; Molecular Oncology; Research Review; Academic Research.

Introduction

Cancer biomarker research covers the identification and evaluation of measurable biological characteristics associated with cancer risk, detection, classification, prognosis, treatment response, or disease progression. The field has developed alongside advances in molecular biology, genomics, proteomics, imaging, immunology, and analytical technologies. Reviews of cancer biomarkers emphasize that a candidate biomarker must be evaluated systematically before it can be considered suitable for routine clinical application. [2]

Recent literature describes an expanding biomarker landscape involving conventional protein markers as well as genomic and transcriptomic targets, circulating tumour DNA, circulating tumour cells, microRNAs, and liquid-biopsy technologies. These developments have broadened the possibilities for early detection, molecular characterization, prognosis, treatment selection, and disease monitoring, while also creating requirements for robust validation and reproducibility. [4]

Research Profile

The supplied research profile identifies STAVROS DERDAS with AEGEAN COLLEGE in Greece and associates the researcher with Cancer Biomarker as the principal subject area for this recognition profile. The Scopus information supplied for the profile records 17 documents, 487 citations, and an h-index of 9. Scopus author metrics are database-dependent and can change as publications are indexed, records are corrected, and citations are added. [1]

Research Contributions

The research area represented in this profile is situated within the broader field of cancer biomarker science. Biomarker research can encompass the identification of measurable molecular or biological characteristics, development of analytical assays, assessment of diagnostic or prognostic performance, evaluation of treatment-response indicators, and investigation of biomarkers for disease surveillance. Established literature stresses the distinction between analytical validity, clinical validity, and clinical utility when evaluating candidate biomarkers. [2]

  • Cancer biomarker research connects molecular characteristics with clinically relevant questions involving detection, diagnosis, prognosis, treatment response, and monitoring.
  • Modern biomarker discovery increasingly incorporates genomic, transcriptomic, proteomic, and circulating molecular information. [4]
  • Biomarker development requires appropriate analytical and clinical validation before translation into clinical practice. [2]
  • Emerging detection platforms include liquid biopsy and biosensor-based approaches, which continue to be evaluated for sensitivity, specificity, portability, and clinical applicability. [5]

Publications

The supplied Scopus profile records 17 documents associated with Scopus Author ID 6505579887. The available information does not provide a verified publication-by-publication bibliography for STAVROS DERDAS; therefore, individual publications are not attributed to the researcher in this article without documentary confirmation. The document count is presented as a bibliometric profile indicator rather than as a substitute for a complete publication list. [1]

For contextual purposes, peer-reviewed literature demonstrates the breadth of the cancer biomarker field. Reviews have examined biomarker development, emerging genomic and molecular approaches, biosensor technologies, and the clinical implications of biomarker-guided precision oncology. [2] [3] [5]

Research Impact

The supplied bibliometric record reports 487 citations across 17 documents and an h-index of 9. These figures indicate citation activity associated with the identified Scopus author record, while their interpretation should take into account disciplinary citation patterns, publication types, database coverage, and the timing of indexing. [1]

Within cancer research, biomarker studies can contribute to translational research by providing measurable indicators for biological characterization and clinical decision-making. Contemporary reviews emphasize the continuing movement from conventional protein-based markers toward integrated genomic, transcriptomic, proteomic, and liquid-biopsy approaches. [3] [4] The scientific impact of individual biomarker research ultimately depends on factors such as reproducibility, independent validation, clinical relevance, methodological quality, and successful translation.

Award Suitability

The Best Review Article Award is presented here in relation to the research profile supplied for STAVROS DERDAS, with Cancer Biomarker identified as the relevant subject area. The profile contains bibliometric evidence of scholarly activity, including 17 documents, 487 citations, and an h-index of 9. [1] The suitability of a review-article recognition should additionally be assessed against the specific award’s formal criteria, including the documented review article or articles, originality and synthesis of the literature, methodological rigor, scholarly contribution, relevance to oncology and cancer research, and evidence supporting the submitted work.

The associated event is the International Research Awards on Oncology and Cancer Research. The event website describes the awards as recognizing researchers, scientists, academicians, healthcare professionals, and innovators working across areas including oncology, cancer therapy, precision medicine, immunotherapy, and translational science. [6] The award profile should therefore be understood as an academic recognition page based on the supplied researcher information rather than as an independent assessment of the researcher’s complete scholarly record.

Conclusion

STAVROS DERDAS, affiliated with AEGEAN COLLEGE in Greece, is represented in this profile within the research area of Cancer Biomarker. The supplied Scopus information records 17 documents, 487 citations, and an h-index of 9 under Author ID 6505579887. Cancer biomarker research remains an interdisciplinary area involving molecular discovery, analytical development, clinical validation, and translational oncology. [2] [3] The Best Review Article Award recognition is contextualized by this documented research profile and by the broader relevance of biomarker research to oncology and cancer research.

References

  1. Elsevier. (n.d.). Scopus author details: STAVROS DERDAS, Author ID 6505579887. Scopus.https://www.scopus.com/authid/detail.uri?authorId=6505579887
  2. Henry, N. L., & Hayes, D. F. (2012). Cancer biomarkers. Molecular Oncology, 6(2), 140–146. DOI: 10.1016/j.molonc.2012.01.010.https://doi.org/10.1016/j.molonc.2012.01.010
  3. Passaro, A., et al. (2024). Cancer Biomarkers: Emerging Trends and Clinical Implications for Personalized Treatment. Cell, 187(7), 1617–1635. DOI: 10.1016/j.cell.2024.02.041.https://doi.org/10.1016/j.cell.2024.02.041
  4. Basheeruddin, M., Qausain, S., Anjankar, A., & Khan, F. I. (2026). Advancements in cancer biomarker discovery over fifteen years: diagnostics and prognostic approach in somatic cancer. Oncology Reviews, 20, 1809836. DOI: 10.3389/or.2026.1809836.https://doi.org/10.3389/or.2026.1809836
  5. Cancer biomarkers and their biosensors: A comprehensive review. TrAC Trends in Analytical Chemistry, 158, 116813 (2023). DOI: 10.1016/j.trac.2022.116813.https://doi.org/10.1016/j.trac.2022.116813
  6. Pencis. (n.d.). International Research Awards on Oncology and Cancer Research. Pencis.https://oncology.pencis.com/

Yasemin DADAS | Cancer Cell Biology | Innovative Research Award

Published on by Oncology

Innovative Research Award

Yasemin Dadas 
Nigde Omer Halisdemir University, Turkey
Yasemin Dadas
Affiliation Department of Obstetrics and Gynecology, Faculty of Medicine, Nigde Omer Halisdemir University
Country Turkey
Scopus ID 60163710500
Documents 2
Citations 3
h-index 1
Subject Area Cancer Cell Biology
Event International Research Awards on Oncology and Cancer Research

Yasemin Dadas is a researcher and academic physician affiliated with the Department of Obstetrics and Gynecology, Faculty of Medicine, Nigde Omer Halisdemir University, Turkey. Publicly available academic records associate her research with obstetrics and gynecology and with oncology-related questions, including fertility preservation in women with pelvic gynecologic malignancies. Her institutional affiliation is also listed in the academic staff records of Nigde Omer Halisdemir University. [1] [2]

Abstract

Yasemin Dadas is affiliated with the Department of Obstetrics and Gynecology at Nigde Omer Halisdemir University in Turkey. Her documented scholarly work includes research involving reproductive medicine and gynecologic oncology. A 2026 systematic review co-authored by Dadas examines fertility preservation strategies for women with pelvic gynecologic malignancies and considers the integration of oncologic surgery, chemotherapy, radiotherapy, and multidisciplinary care. [2] Her publication record also includes research concerning progesterone protocols used in frozen-thawed embryo transfer preparation. [3]

Keywords

Yasemin Dadas; Cancer Cell Biology; gynecologic oncology; pelvic gynecologic malignancies; fertility preservation; reproductive medicine; obstetrics and gynecology; oncology research; multimodal cancer care; Nigde Omer Halisdemir University.

Introduction

Research at the intersection of gynecology, reproductive medicine, and oncology addresses clinical questions that affect both cancer treatment and reproductive potential. In pelvic gynecologic malignancies, fertility preservation can form part of multidisciplinary treatment planning, particularly when surgery and subsequent anticancer therapies may affect reproductive function. Dadas’ published work contributes to this clinical research area through a systematic review focused on fertility preservation strategies in women undergoing multimodal oncologic treatment. [2]

Research Profile

The available academic record places Yasemin Dadas within obstetrics and gynecology, with published research spanning reproductive medicine and subjects relevant to gynecologic oncology. Her institutional profile identifies her as a faculty member in the Department of Obstetrics and Gynecology at Nigde Omer Halisdemir University. [1]

Research Contributions

A principal documented contribution is the systematic examination of fertility preservation strategies for women with pelvic gynecologic malignancies. The review evaluates approaches used around pelvic oncologic surgery and subsequent treatment and emphasizes the need to consider reproductive outcomes alongside oncologic management. [2]

Publications

The two publications listed above are independently identifiable through scholarly bibliographic sources and correspond with the supplied Scopus document count. The 2026 systematic review is indexed in PubMed and PubMed Central, while the 2025 Biomedicines article is also indexed in PubMed. [2] [3]

Research Impact

The supplied bibliometric profile reports 2 documents, 3 citations, and an h-index of 1 for Scopus Author ID 60163710500. These indicators describe the citation record associated with the supplied profile and should be interpreted in relation to publication age, field-specific citation patterns, and the size of the documented publication portfolio.

Award Suitability

For an academic recognition profile under the Innovative Research Award, the documented record provides identifiable evidence of research activity in obstetrics and gynecology, reproductive medicine, and gynecologic oncology. In particular, the systematic review on fertility preservation in pelvic gynecologic malignancies directly addresses a cancer-care research question and incorporates multiple dimensions of oncologic treatment. [2]

Conclusion

Yasemin Dadas has a documented academic profile at Nigde Omer Halisdemir University in Turkey, with research spanning obstetrics and gynecology, reproductive medicine, and gynecologic oncology. Her published work includes a systematic review addressing fertility preservation in women with pelvic gynecologic malignancies and a study of progesterone protocols for frozen-thawed embryo transfer. [2] [3]

1.Scopus Author Profile — Yasemin Dadas, Author ID 60163710500

2. Comparison of Different Progesterone Protocols for Luteal Support

3.  International Research Awards on Oncology and Cancer Research — Award Website

References

1.Niğde Ömer Halisdemir Üniversitesi. (n.d.). Faculty of Medicine — Academic Staff / Department of Surgical Medical Sciences. The institutional listing        identifies Yasemin Dadaş within the Department of Obstetrics and Gynecology.
    https://www.ohu.edu.tr/facultyofmedicine/academic-staff2

2.Dadas, Y., Oner, G., Karaman, E., Ayan, D., Doganay, H. N., Bayram, E., Tunca Sanlier, N., & Kulular, B. (2026). Fertility Preservation Strategies in          Women with Pelvic Gynecologic Malignancies Undergoing Multimodal Oncologic Treatment: A Systematic Review. Cancers, 18(7), 1142.
    https://doi.org/10.3390/cancers18071142

3.Oner, G., Karaman, E., Kulular, B., Dadas, Y., & Doganay, H. N. (2025). Comparison of Different Progesterone Protocols for Luteal Support in Frozen-      Thawed Embryo Transfer Preparation. Biomedicines, 13(10), 2487.
     https://dergipark.org.tr/tr/pub/@yasemin-dadas

4.Elsevier. (n.d.). Scopus Author Details: Yasemin Dadas, Author ID 60163710500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=60163710500

5.International Research Awards on Oncology and Cancer Research. (n.d.). Official Award Website.
    https://oncology.pencis.com/

 

Celal Özbek Çakır | chemotherapy | Innovative Research Award

Published on by Oncology

Innovative Research Award

Celal Özbek Çakır
Karamanoğlu Mehmet Bey University, Turkey

Celal Özbek Çakır
Affiliation Karamanoğlu Mehmet Bey University
Country Turkey
Subject Area Chemotherapy
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-3618-6033

Celal Özbek Çakır is a researcher affiliated with Karamanoğlu Mehmet Bey University in Turkey whose stated subject area is chemotherapy. This recognition profile presents the researcher in the context of the Innovative Research Award associated with the International Research Awards on Oncology and Cancer Research. The profile is based on the identifying and affiliation information supplied for the award record, together with persistent researcher-identification information available through ORCID. [1]

Abstract

This academic recognition profile concerns Celal Özbek Çakır of Karamanoğlu Mehmet Bey University, Turkey, with chemotherapy identified as the principal subject area. The profile is associated with the Innovative Research Award within the International Research Awards on Oncology and Cancer Research. The researcher is identified through the ORCID persistent identifier 0000-0002-3618-6033, which provides a standardized mechanism for distinguishing researchers and connecting their scholarly activities with an individual record. [2]

Keywords

Keywords: chemotherapy, oncology research, cancer research, cancer treatment, anticancer therapy, therapeutic research, drug response, oncology pharmacology, innovative research, translational oncology, Karamanoğlu Mehmet Bey University, Turkey, Innovative Research Award.

Introduction

Chemotherapy is an established component of cancer treatment research and encompasses the investigation and clinical application of medicines that can interfere with the growth, division, or survival of cancer cells. Contemporary oncology research also examines how therapeutic approaches can be optimized through combination strategies, treatment sequencing, biomarker-informed approaches, and improved management of treatment-related effects. The National Cancer Institute describes chemotherapy as a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. [3]

Research Profile

Celal Özbek Çakır is affiliated with Karamanoğlu Mehmet Bey University in Turkey. The supplied academic profile identifies chemotherapy as the relevant subject area and associates the researcher with the Innovative Research Award. The researcher’s ORCID iD is 0000-0002-3618-6033. ORCID identifiers are persistent identifiers designed to distinguish researchers and support reliable attribution of scholarly work across systems. [2]

Research Contributions

The stated research area of chemotherapy places the profile within cancer-treatment research. Potential contribution areas in this domain include the study of anticancer agents, mechanisms of drug action, treatment resistance, combination therapies, therapeutic optimization, and strategies for improving the safety or effectiveness of cancer treatment. However, individual contribution claims require supporting publication or institutional evidence and should not be attributed to the researcher without verification.

Publications

A verified publication list was not supplied as part of the profile data. Consequently, specific articles, journal titles, publication dates, citation counts, and DOI records are not attributed to Celal Özbek Çakır in this section. A complete publication assessment should be conducted using the researcher’s ORCID record and authoritative bibliographic databases, with author identity and affiliation checked for each publication. [1] [2]

Research Impact

Research impact in oncology may be reflected through several forms of scholarly and practical contribution, including peer-reviewed publications, citation and reuse of research findings, methodological advances, collaborative research, translational applications, and contributions to evidence used in cancer treatment. Citation counts and h-index values can be useful descriptive indicators, but they should be interpreted in relation to discipline, career stage, database coverage, and publication history.

Award Suitability

The Innovative Research Award is presented in the context of the International Research Awards on Oncology and Cancer Research. Based on the supplied profile information, the researcher’s stated subject area of chemotherapy is directly situated within cancer-treatment research. This establishes topical relevance to an oncology-focused research recognition program.

Conclusion

Celal Özbek Çakır is identified in the supplied award profile as a researcher affiliated with Karamanoğlu Mehmet Bey University, Turkey, with chemotherapy as the stated subject area and ORCID iD 0000-0002-3618-6033. The profile connects the researcher with the Innovative Research Award under the International Research Awards on Oncology and Cancer Research. [2]

References

  1. 1.Elsevier. (n.d.): Abstract and citation database and author profiles. Scopus.
    https://www.scopus.com/
  2. 2.ORCID. (n.d.). ORCID: Connecting research and researchers. ORCID.
    https://orcid.org/0000-0002-3618-6033
  3. 3.National Cancer Institute.(n.d.).Chemotherapy to Treat Cancer. National Cancer Institute.
    https://www.cancer.gov/about-cancer/treatment/types/chemotherapy
  4. 4.International DOI Foundation. (n.d.). DOI Handbook. International DOI Foundation.
    https://www.doi.org/the-identifier/resources/factsheets/doi-handbook
      5. International Research Awards on Oncology and Cancer Research
       https://doi.org/10.1179/016164107X159225

Rabbani Syed | Pharmaco-Oncology | Innovative Research Award

Published on by Oncology

Innovative Research Award

Rabbani Syed
King Saud University, Saudi Arabia

Rabbani Syed
Affiliation King Saud University
Country Saudi Arabia
Scopus ID 35751491100
Documents 95
Citations 1,703
h-index 21
Subject Area Pharmaco-Oncology
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-4695-0645

The Innovative Research Award recognizes research activity that contributes to the development of new knowledge, methodologies, or applications within a defined academic discipline. This profile presents the available research information associated with Rabbani Syed of King Saud University, Saudi Arabia, in the context of the International Research Awards on Oncology and Cancer Research.

Abstract

This academic recognition profile documents the supplied research information of Rabbani Syed, affiliated with King Saud University in Saudi Arabia. The researcher is associated with the subject area of Pharmaco-Oncology and has been proposed in connection with the Innovative Research Award. The available bibliometric information includes 95 documents, 1,703 citations, and an h-index of 21. These indicators offer a measurable description of scholarly activity but do not, by themselves, establish the originality or practical effectiveness of individual studies. Further evaluation requires examination of publications, research methods, and documented contributions.

Keywords

Keywords: Innovative Research Award, Rabbani Syed, King Saud University, Saudi Arabia, Pharmaco-Oncology, cancer research, oncology, pharmaceutical research, bibliometrics, scholarly publications, therapeutic research, research recognition.

Introduction

Pharmaco-Oncology encompasses research involving medicines, drug mechanisms, therapeutic development, and pharmacological strategies relevant to cancer care. Innovation in this field may involve the discovery of candidate compounds, investigation of drug responses, improvements in drug-delivery systems, or the evaluation of treatment-related biological mechanisms. Research recognition in this area requires consideration of the scientific question, methodological rigor, reproducibility, and potential relevance to oncology. [2]

Research Profile

Rabbani Syed is identified in the supplied information as a researcher affiliated with King Saud University, Saudi Arabia. The provided Scopus author identifier is 35751491100, while the ORCID identifier is 0000-0003-4695-0645. The supplied profile statistics indicate 95 documents, 1,703 citations, and an h-index of 21. These figures should be interpreted with reference to the date of retrieval and the specific author record. [1]

Research Contributions

The supplied subject classification places the researcher within Pharmaco-Oncology. However, detailed information about specific research projects, experimental findings, patented technologies, clinical investigations, or methodological innovations has not been provided. Consequently, individual contributions cannot be independently described in detail. A comprehensive assessment would examine the originality of the research questions, the quality of the evidence, and the relevance of reported findings to oncology and pharmaceutical science. [3]

Publications

The supplied information reports a total of 95 documents associated with the researcher’s academic record. A complete publication list, including article titles, journals, publication dates, co-authors, and digital object identifiers, was not supplied for this profile. The Scopus author record may provide a starting point for examining indexed publications and related citation information. Publication-level verification is necessary before attributing specific scientific findings or research achievements.

Research Impact

The reported citation count of 1,703 and h-index of 21 provide quantitative indicators of the researcher’s documented scholarly visibility. Citation measures can assist in describing patterns of academic attention, but they may be influenced by publication age, disciplinary practices, collaboration patterns, and database coverage. They should therefore be considered alongside qualitative evidence, including research reproducibility, scientific influence, and documented applications. [4]

Award Suitability

The Innovative Research Award is associated with research that demonstrates originality and meaningful advancement within a relevant field. The supplied affiliation, subject area, publication count, citation count, and h-index provide contextual information for an academic review. A formal award assessment should additionally consider the nominee’s documented innovations, supporting publications, research significance, and compliance with the event’s eligibility criteria. The available information alone does not establish the outcome of an award evaluation.

Conclusion

Rabbani Syed is identified in the supplied data as a King Saud University researcher working in the subject area of Pharmaco-Oncology. The reported record includes 95 documents, 1,703 citations, and an h-index of 21. These metrics summarize selected aspects of scholarly activity. Further information about research innovations, individual publications, and documented scientific outcomes would be required to develop a more comprehensive academic assessment in relation to the Innovative Research Award.

References

  1. Elsevier. (n.d.). Scopus author details: Rabbani Syed, Author ID 35751491100. Scopus.https://www.scopus.com/authid/detail.uri?authorId=35751491100
  2. National Cancer Institute. (n.d.). Drug therapy and cancer treatment research. National Cancer Institute.https://www.cancer.gov/about-cancer/treatment/types
  3. Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46.https://doi.org/10.1158/2159-8290.CD-21-1059
  4. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.https://doi.org/10.1073/pnas.0507655102
  5. ORCID. (n.d.). ORCID: Connecting research and researchers. ORCID.https://orcid.org/0000-0003-4695-0645

Rahul Kota | Cancer Genetics | Young Scientist Award

Published on by Oncology

Young Scientist Award

Rahul Kota
QIS College of Pharmacy, India

Rahul Kota
Affiliation QIS College of Pharmacy
Country India
Subject Area Cancer Genetics
Event International Research Awards on Oncology and Cancer Research
ORCID 0009-0007-0528-4865

Rahul Kota is affiliated with QIS College of Pharmacy in India and is identified with the subject area of cancer genetics. Cancer genetics examines the relationship between genetic variation, genomic alterations, inherited susceptibility, and the development or progression of cancer. The field contributes to understanding molecular mechanisms of disease and can support the development of improved approaches to cancer risk assessment, diagnosis, classification, and treatment. [1]

Abstract

This academic recognition profile concerns Rahul Kota of QIS College of Pharmacy, India, whose stated subject area is Cancer Genetics. Cancer genetics is an interdisciplinary area within biomedical and oncology research that investigates genetic and genomic factors associated with cancer initiation, susceptibility, progression, and therapeutic response. Modern cancer research increasingly integrates molecular genetics with genomic technologies to characterize tumor biology and identify clinically relevant alterations. [1]

Keywords

Cancer Genetics; cancer genomics; oncology research; genetic variation; tumor genetics; molecular oncology; genomic medicine; cancer susceptibility; precision oncology; biomedical research; young scientist; cancer research.

Introduction

Cancer is fundamentally a disease involving alterations to cellular genetic and regulatory processes. Genetic changes may arise through inherited variation or accumulate during an individual’s lifetime, with combinations of genomic alterations influencing tumor development and biological behavior. Large-scale genomic studies have demonstrated substantial molecular diversity among cancers, supporting the classification of tumors according to their underlying molecular characteristics. [2]

Research Profile

Rahul Kota is associated with QIS College of Pharmacy and has been identified for this profile under the research area of Cancer Genetics. The supplied researcher identifier is ORCID 0009-0007-0528-4865, providing a persistent digital identifier that can be used to distinguish a researcher from other individuals with similar names.

Research Contributions

Within cancer genetics, research contributions may encompass investigation of inherited and acquired genetic alterations, molecular mechanisms of tumor development, genetic determinants of cancer susceptibility, genomic characterization of tumors, and the interpretation of molecular information for oncology applications. Cancer-associated genetic alterations can affect pathways involved in cell proliferation, DNA repair, apoptosis, and other processes relevant to malignant transformation. [3]

Publications

No verified publication list was supplied for this profile. Consequently, individual publications, journal articles, citation counts, and DOI records are not attributed to Rahul Kota in order to avoid conflating publications by researchers with similar names.For a formal academic evaluation, publications should be verified through authoritative scholarly records and matched using persistent identifiers, institutional affiliation, subject area, authorship information, and DOI metadata where available.

Research Impact

Cancer genetics has substantial relevance to contemporary oncology because genomic information can improve understanding of disease heterogeneity and provide a foundation for molecularly informed clinical research. The identification and interpretation of cancer-associated alterations have become important components of translational oncology and precision-medicine research. [2] [3]

Award Suitability

The Young Scientist Award is presented here within the context of the International Research Awards on Oncology and Cancer Research. Rahul Kota’s supplied affiliation with QIS College of Pharmacy and stated specialization in Cancer Genetics establish a subject-area connection with oncology and cancer research.Based solely on the supplied information, the profile demonstrates thematic alignment with the award’s oncology research scope. A complete award assessment would additionally require verification of eligibility criteria, research outputs, publication record, originality of contributions, and other evaluation requirements established by the award program.

Conclusion

Rahul Kota, affiliated with QIS College of Pharmacy in India, is profiled within the field of Cancer Genetics for consideration under the Young Scientist Award associated with the International Research Awards on Oncology and Cancer Research. The available information supports a clear subject-area relationship with oncology research. Further assessment of scholarly achievement should be based on verified publication, citation, authorship, and research-impact evidence.

References

1. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31–46.
        https://doi.org/10.1158/2159-8290.CD-21-1059

2. The Cancer Genome Atlas Research Network. (2013). The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genetics, 45, 1113–  1120.                         https://doi.org/10.1038/ng.2764

3. National Cancer Institute. (n.d.). Precision Medicine in Cancer. National Institutes of Health.
         https://www.cancer.gov/research/infrastructure/precision-medicine

4. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., Jr., & Kinzler, K. W. (2013). Cancer Genome Landscapes. Science, 339(6127),          1546–1558.
         https://doi.org/10.1126/science.1235122

5. ORCID. (n.d.). ORCID: Connecting Research and Researchers.
          https://orcid.org/

Eisa Mohammadi | Oncology Nursing | Best Researcher Award

Published on by Oncology

Best Researcher Award

Eisa Mohammadi
Tarbiat Modares University, Iran
Eisa Mohammadi
Affiliation Tarbiat Modares University
Country Iran
Scopus ID 6506581702
Documents 308
Citations 5,456
h-index 37
Subject Area Oncology Nursing
Event International Research Awards on Oncology and Cancer Research
Scopus Author Profile

Eisa Mohammadi is an academic researcher affiliated with Tarbiat Modares University in Iran whose scholarly activities are associated with nursing, patient care, clinical practice, and health-related qualitative research. His publication record includes investigations addressing clinical nursing practice, patient experiences, supportive care, professional competencies, and psychosocial dimensions of health care.  [1]

Abstract

This academic recognition profile examines the research record of Eisa Mohammadi in relation to the Best Researcher Award within the International Research Awards on Oncology and Cancer Research. His work reflects a nursing-centered research perspective incorporating patient experiences, clinical interventions, care quality, symptom assessment, psychosocial support, and professional nursing practice. [2]

Keywords

Oncology nursing; cancer care; nursing research; patient-centered care; chemotherapy; quality of life; clinical nursing; supportive care; symptom management; psychosocial oncology; spiritual care; qualitative research; nursing intervention; patient experience.

Introduction

Oncology nursing integrates clinical knowledge with symptom management, education, psychological support, communication, rehabilitation, and quality-of-life assessment. Research in this field increasingly addresses not only disease treatment but also how patients and families experience illness and care. Mohammadi’s nursing scholarship demonstrates engagement with these human and clinical dimensions. A study examining a healing program for patients receiving chemotherapy, for example, investigated quality-of-life outcomes and identified Mohammadi with the Department of Nursing at Tarbiat Modares University. [2]

Research Profile

The supplied Scopus metrics identify Mohammadi with 308 documents, 5,456 citations, and an h-index of 37. These bibliometric indicators describe a substantial publication record and recurring citation of his scholarly output. His research profile spans nursing practice and patient-focused health research, with particular relevance to qualitative investigation, clinical care processes, professional nursing competencies, and supportive interventions. Independent bibliographic records also associate Eisa Mohammadi with Tarbiat Modares University and a broad body of nursing scholarship. [1]

Research Contributions

Mohammadi’s contributions illustrate how nursing research can strengthen evidence-based clinical practice. Research on pain assessment investigated organizational and educational approaches for improving nurses’ assessment skills, emphasizing the importance of structured clinical competency development. [3] Other work has examined spiritual care as a nursing concept, an area relevant to comprehensive cancer care because serious illness frequently introduces existential, emotional, cultural, and spiritual concerns that influence patient experiences and supportive-care requirements. [4]

Publications

Selected publications demonstrate methodological and clinical diversity. Farahani, Alhani, and Mohammadi evaluated the establishment of a pain committee and its influence on pediatric nurses’ pain-assessment skills in the International Journal of Nursing Practice. [3] Samari, Mohammadi, and Ahmadi reported on a healing program and quality of life among chemotherapy patients. [2] Mohammadi has also contributed to qualitative research examining patient experiences and barriers affecting engagement with health-care services. [5]

Research Impact

The reported citation count and h-index indicate continuing scholarly visibility across nursing and health-care literature. Research impact in nursing is additionally reflected through applicability to professional practice, patient safety, symptom assessment, supportive care, and educational interventions. Mohammadi’s work addresses several of these dimensions, combining empirical investigation with clinically meaningful questions.

Award Suitability

Assessment for a Best Researcher Award may reasonably consider research productivity, citation influence, methodological contribution, continuity of scholarship, and relevance to the award field. Based on the supplied bibliometric indicators and identifiable publications, Mohammadi presents a profile characterized by extensive scholarly activity and nursing-focused clinical research.

Conclusion

Eisa Mohammadi’s academic profile represents sustained engagement with nursing science, clinical practice, patient experience, and supportive health care. His research record includes contributions relevant to cancer treatment experiences, quality of life, nursing assessment, and holistic care. Within an oncology-focused academic recognition framework, these contributions establish a clear interdisciplinary relationship between nursing research and comprehensive cancer care.

References

1.Elsevier. (n.d.). Scopus author details: Eisa Mohammadi, Author ID 6506581702. Scopus.
        https://www.scopus.com/pages/authors/6506581702

2.Farahani, P. V., Alhani, F., & Mohammadi, E. (2014). Effect of establishing pain committee on the pain assessment skills of paediatric nurses. International          Journal of Nursing Practice, 20(5), 499–509:
        https://doi.org/10.1111/ijn.12191

3.Ramezani, M., Ahmadi, F., Mohammadi, E., & Kazemnejad, A. (2014). Spiritual care in nursing: A concept analysis. International Nursing Review, 61, 211–           219. Wiley Online Library.

       https://onlinelibrary.wiley.com/

4.Saki, M., Kermanshahi, S. M. K., Mohammadi, E., & Mohraz, M. (2015). Explaining the hindering factors for accepting the disease, a barrier for the                       HIV/AIDS patients to seek treatment:

       https://doi.org/10.4103/2345-5756.231401

5.National Library of Medicine. (n.d.). PubMed record: Effect of establishing pain committee on the pain assessment skills of paediatric nurses. PubMed,                 PMID 24124759.

       https://pubmed.ncbi.nlm.nih.gov/24124759/

LEANDRO RESENDE | Oncology and precision medicine | Innovative Research Award

Published on by Oncology

Innovative Research Award

LEANDRO RESENDE
Rede Dor

LEANDRO RESENDE
Affiliation Rede Dor
Country Brazil
Scopus ID 57188977624
Documents 5
Citations 35
h-index 3
Subject Area Oncology and precision medicine
Event International Research Awards on Oncology and Cancer Research
Scopus Author Profile

LEANDRO RESENDE is a researcher affiliated with Rede Dor in Brazil whose documented scholarly profile is associated with oncology and precision medicine.The Innovative Research Award profile presents this research activity within the broader context of contemporary cancer science, where molecular characterization, individualized treatment strategies, biomarkers, and evidence-based clinical decision-making increasingly intersect. Precision oncology seeks to connect biological information with clinically meaningful therapeutic choices. [1]

Abstract

The Innovative Research Award profile recognizes the research record of LEANDRO RESENDE, affiliated with Rede Dor, Brazil, in the field of oncology and precision medicine. The documented Scopus profile reports five scholarly documents, 35 citations, and an h-index of 3. [1] These indicators provide a bibliometric snapshot of published research and citation activity.Within modern oncology, precision medicine emphasizes the integration of molecular, clinical, and pathological information to support more individualized approaches to cancer investigation and treatment.

Keywords

  • Innovative Research Award
  • Oncology
  • Precision Medicine
  • Cancer Research
  • Biomedical Research
  • Research Impact

Introduction

Cancer research increasingly depends on interdisciplinary approaches that connect molecular biology, clinical medicine, pathology, genomics, and computational analysis. Precision medicine has developed as an important framework for identifying biological differences between tumors and using those differences to inform research and therapeutic strategies. [3]Against this background, researchers working across oncology contribute to a continually expanding evidence base.

Research Profile

LEANDRO RESENDE is affiliated with Rede Dor in Brazil and is represented in Scopus under Author ID 57188977624. The supplied profile records five documents, 35 citations, and an h-index of 3. [1] The stated subject area is oncology and precision medicine, placing the research profile within a clinically and scientifically significant field.

Research Contributions

Contemporary cancer frameworks emphasize multiple interacting characteristics of malignant disease, including genomic instability, cellular signaling, immune interactions, and the tumor microenvironment. [3]The documented bibliometric record offers measurable evidence of scholarly dissemination, while the specific scientific significance of individual publications should be evaluated through their methods, findings, citations, and subsequent use by other researchers.

Publications

The supplied Scopus record identifies five documents associated with the researcher. [1] Because complete publication titles, journal information, publication years, and DOI identifiers were not supplied with the profile data, this article does not assign specific publication details that cannot be independently established from the provided record.

Research Impact

The reported total of 35 citations indicates that the indexed documents have been cited within the scholarly literature. The h-index of 3 further describes a citation distribution in which at least three documents have each received at least three citations, subject to the indexing and counting methodology used by the database. [1]Citation metrics are useful descriptive measures but do not independently determine scientific quality or societal impact.

Award Suitability

The supplied research profile is aligned thematically with an award focused on oncology and cancer research because the stated subject area is oncology and precision medicine. The documented publication and citation record provides an objective basis for describing established scholarly activity. [1]Final award assessment should be based on the organizer’s published eligibility criteria, submitted evidence, peer or committee evaluation, and the originality and significance of the candidate’s research.

Conclusion

LEANDRO RESENDE’s supplied academic profile documents research activity associated with Rede Dor, Brazil, and the fields of oncology and precision medicine. The Scopus record reports five documents, 35 citations, and an h-index of 3, providing a concise bibliometric description of the researcher’s indexed scholarly output. [1]The Innovative Research Award profile places these activities within the wider development of precision oncology and evidence-based cancer research.

References

  1. Elsevier. (n.d.). Scopus author details: LEANDRO RESENDE, Author ID 57188977624. Scopus.
    https://www.scopus.com/pages/authors/57188977624
  2. National Cancer Institute. (n.d.). Precision Medicine in Cancer Treatment. National Cancer Institute.
    https://www.cancer.gov/about-cancer/treatment/types/precision-medicine
  3. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cell, 185(1), 31–41. DOI: 10.1016/j.cell.2021.12.029.
    https://doi.org/10.1016/j.cell.2021.12.029
  4. Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17, 507–522. DOI: 10.1038/nrg.2016.86.
    https://doi.org/10.1038/nrg.2016.86
  5. International Research Awards on Oncology and Cancer Research. (n.d.). Official Award Website.
    https://oncology.pencis.com/